Login / Signup

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer.

Kyoung-Ho PyoSun Min LimChae-Won ParkHa-Ni JoJae Hwan KimMi-Ran YunDohee KimChun-Feng XinWongeun LeeBianca GheorghiuMin Hee HongHye Ryun KimHyo Sup ShimMi JangSung Sook LeeByoung Chul Cho
Published in: Journal for immunotherapy of cancer (2021)
ALK-positive tumors progressing on ceritinib is not immunogenic enough to respond to immune checkpoint inhibitors.
Keyphrases
  • advanced non small cell lung cancer
  • combination therapy
  • epidermal growth factor receptor
  • tyrosine kinase